Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek May 14, 2007 Arlene Weintraub	Schering-Plough Climbs Out Of Its Sickbed Fred Hassan said getting drugmaker Schering-Plough on its feet might take years. Investors are beginning to see the virtues of patience
The Motley Fool March 11, 2004 Ben McClure	Quality Earnings Count Here are three telltale signs of strong earnings. This reporting period, it's worthwhile taking a peek behind the earnings. Here are three telltale signs of earnings "quality" to guide your stock picks.
BusinessWeek December 22, 2003 Robert Barker	A Stimulant For Depressed Drug Stocks? For a bunch of can't-miss stocks, the big drugmakers sure did miss out on 2003's bull run. The dozen drug companies in the Standard & Poor's 500-stock index have returned 10% this year, vs. the index' 22%. But the market is now failing to credit the companies' strengths.
The Motley Fool January 13, 2004 Jeff Hwang	Eon Labs' Potent Potential The generic drug maker's fourth-quarter estimates spiked higher.
The Motley Fool January 25, 2005 Stephen D. Simpson	Schering-Plough Turning a Corner The troubled pharmaceutical company begins to show signs of life. Investors looking for a more stable play would do well to look at other shares instead.
The Motley Fool January 6, 2004 Jeff Hwang	Hollywood Hammered Hollywood Entertainment warns again, but are its shares cheap at nine times earnings?
The Motley Fool October 24, 2005 Stephen D. Simpson	Vytorin Lifts Schering-Plough While the pharma is now officially in a turnaround phase, the news may already be baked into the stock.
The Motley Fool January 23, 2004 Rex Moore	Visteon Struggles On The parts maker reports loss, but lessens Ford reliance.
The Motley Fool December 18, 2003 Dave Marino-Nachison	Standing by Family Dollar Investors may be catching on to this discounted Dollar retailer.
The Motley Fool February 12, 2004 Alyce Lomax	Depressing Year for Glaxo The pharmaceutical giant forecasts three lackluster quarters as copycats attack.
The Motley Fool March 11, 2004 Seth Jayson	Dillard's Still Dragging Sales, earnings, and comps are down -- but the stock is up. Go figure.
The Motley Fool April 20, 2004 Alyce Lomax	Pfizer's Fight First-quarter earnings give mixed messages on the drug maker's meds.
The Motley Fool March 31, 2004 Alyce Lomax	Circuit City Reloaded? Investors grab onto hope, but it still seems too early to call a turnaround.
The Motley Fool April 15, 2004 Rich Smith	Texas Instruments Stands Out The chip maker distinguishes itself with solid Q1 results.
The Motley Fool February 23, 2004 Alyce Lomax	Onward, Coach! The retailer boosts guidance on a strong spring line and success in Japan.
The Motley Fool February 11, 2004 W.D. Crotty	Health-Care Opportunity Health Net looks like a value-priced managed care company.
The Motley Fool March 16, 2004 Seth Jayson	Dollar General Dodges Bullet The discounter pays its way out of an SEC bookkeeping imbroglio with the usual spineless settlement.
The Motley Fool August 4, 2004 W.D. Crotty	The Brink of Suspense Brink's offers a big surprise in today's earnings announcement.
The Motley Fool June 21, 2004 Seth Jayson	Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.
The Motley Fool July 30, 2004 Rich Smith	Covering Portfolio Recovery Portfolio Recovery Associates' performance over the past six months have been good with earnings of $0.81 per diluted share translating to an earnings growth of nearly 31% over the first half of 2003.
The Motley Fool April 19, 2004 Rick Aristotle Munarriz	Say Yo to Drugs It will be a busy week for the country's leading drug makers as they post their quarterly earnings.
The Motley Fool July 24, 2006 Stephen D. Simpson	Can Schering-Plough Continue to Shine? Cost-cutting and cholesterol drug sales continue apace, but is the company vulnerable? Investors, take note.
The Motley Fool January 26, 2004 Jeff Hwang	On Schwab's Insider Sales After closer inspection, Schwab CEO's plan to sell is no big deal.
The Motley Fool March 30, 2004 Seth Jayson	CarMax Inches Forward CarMax turns out solid numbers, but are its shares worth the going price?
The Motley Fool February 4, 2004 W.D. Crotty	A 99 Cents Solution? You might just get a bargain in the stock of 99 Cents Only Stores.
The Motley Fool May 20, 2004 Steven Mallas	Intuit's Taxing Quarter Net earnings declined and Q4 could see a loss. What should an investor's intuition be saying?
The Motley Fool February 17, 2004 Alyce Lomax	First Health's Second Go Despite a November warning, the company is back on track.
The Motley Fool December 23, 2003 Jeff Hwang	Bad, Bad Baxter The medical products company issues its latest in a series of earnings warnings.
The Motley Fool April 21, 2004 Ben McClure	Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up?
The Motley Fool May 26, 2004 Mark Mahorney	Stay Away From Computer Associates Computer Associates is still far from moving on.
The Motley Fool January 29, 2004 Seth Jayson	Tribune's in Tip-Top Shape Increases in broadcasting lead across-the-board gains for the media company.
The Motley Fool March 1, 2004 Alyce Lomax	Too Hot? According to the news report, the company is launching a new off-mall concept called Justice, to the cheers of analysts. Apparently, this kind of Justice is served by offering merchandise similar to Too's, at prices 20% to 25% lower than those featured in the regular Too stores..
The Motley Fool July 21, 2005 Stephen D. Simpson	Schering Plows Ahead Strong sales are driving this turnaround. As long as the pharma continues to make progress with its legal and regulatory issues and simultaneously continue to deliver solid financial results, the valuation and stock price will likely work themselves out favorably over time.
The Motley Fool January 30, 2007 Brian Lawler	Schering-Plough Pushes Ahead The drugmaker successfully continues with its multi-year turnaround plan. Investors would be smart to take a look at this pharmaceutical turnaround stock before it starts to get noticed again.
The Motley Fool October 23, 2007 Brian Orelli	Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth.
The Motley Fool April 12, 2004 Seth Jayson	Gannett's Ad-vantageous Q1 First-quarter earnings for Gannett, publisher of USA Today and hundreds of other newspapers, show strong increases in advertising revenues across every segment of the company.
The Motley Fool April 16, 2004 Rich Smith	DoubleClick's Pinched Penny Rounding earnings per share can lay traps for unwary investors. Online advertiser DoubleClick becomes a good lesson in why it is best to think of those little ticker symbols scrolling by as pieces of companies rather than little ticker symbols.
BusinessWeek March 20, 2006	Legal Tangle At The Fountain Of Youth There has been new light shed on allegations that Pharmacia Corp. improperly promoted its drug Genotropin to doctors who intended to use it as an anti-aging treatment. The U.S. Justice Dept. is continuing its investigation.
The Motley Fool April 12, 2004 Seth Jayson	Behind the Times The New York Times may have the big name, but compared to some of its peers, the Manhattan media empire looks a bit soft in the earnings department.
The Motley Fool March 23, 2004 W.D. Crotty	Down on Drug News? An FDA advisory on labeling antidepressants shouldn't depress drug stocks.
FDIC FYI May 17, 2002	Ten Largest Thrift Companies Update Earnings of the 10 largest thrift companies increased by $830 million in the first quarter of 2002, to $1.8 billion, from $982 million in the fourth quarter of 2001, when write-downs of intangible assets and large restructuring charges held down earnings...
The Motley Fool March 18, 2004 W.D. Crotty	Williams-Sonoma Pride It may be time to party over the results at Williams-Sonoma.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool March 18, 2004 Brian Gorman	The Drug Cost Conundrum While drug prices continue to climb, the public and its representatives in government are demanding cheaper pharmaceuticals. The industry is not likely to find cover in Medicare biotechnology. Instead, investors should look for drug makers that are finding ways to operate leaner and meaner.
The Motley Fool July 24, 2007 Brian Lawler	Schering Doesn't Slow Schering-Plough continues its strong sales and earnings growth, but it has a big acquisition to digest in coming quarters.
The Motley Fool January 30, 2004 Alyce Lomax	No Hollywood Star Competitive concerns loom over Hollywood Entertainment's long-term growth plans.
The Motley Fool April 19, 2004 Seth Jayson	Lexmark Inks More Profits The printer maker lives up to its buzz and continues to increase earnings.
The Motley Fool January 27, 2004 Seth Jayson	NY Times' Slim Pickings Media conglomerate weathers storms to post modest gains
The Motley Fool February 24, 2004 Seth Jayson	Cloudy Year at Clear Channel The media giant's final report shows flat results.
The Motley Fool June 8, 2004 W.D. Crotty	An Unlucky Alliance Slot-machine maker Alliance Gaming is getting hammered, but it's no loser.